Is NASDAQ:BPMC a Fit for high Growth Investing Strategies?

Our stock screener has spotted BLUEPRINT MEDICINES CORP (NASDAQ:BPMC) as a possible breakout candidate. A technical breakout setup pattern occurs when the stock is consolidating after a nice uptrend. Whether the actual breakout occurs remains to be seen of course, but it may be interesting to keep an eye on NASDAQ:BPMC.

Technical Analysis Observations

Every day ChartMill assigns a Technical Rating to every stock. The score ranges from 0 to 10 and is determined by evaluating multiple technical indicators and properties.

Overall BPMC gets a technical rating of 8 out of 10. BPMC has been one of the better performers in the overall market. Some doubts were observed in the medium time frame, but recent action was again very positive.

• The long and short term trends are both positive. This is looking good!
• Looking at the yearly performance, BPMC did better than 75% of all other stocks.
• BPMC is one of the better performing stocks in the Biotechnology industry, it outperforms 74% of 570 stocks in the same industry.
• BPMC is currently trading in the middle of its 52 week range. The S&P500 Index however is currently trading near new highs, so BPMC is lagging the market.
• In the last month BPMC has a been trading in the 88.05 - 103.55 range, which is quite wide. It is currently trading in the middle of this range, so some resistance may be found above.

For an up to date full technical analysis you can check the technical report of BPMC

How do we evaluate the setup for NASDAQ:BPMC?

ChartMill also assign a Setup Rating to every stock. With this score it is determined to what extend the stock has been trading in a range in the recent days and weeks. This score also ranges from 0 to 10 and is updated daily. The setup score evaluates various short term technical indicators. NASDAQ:BPMC scores a 8 out of 10:

Besides having an excellent technical rating, BPMC also presents a decent setup pattern. We see reduced volatility while prices have been consolidating in the most recent period. There is a resistance zone just above the current price starting at 100.83. Right above this resistance zone may be a good entry point. There is a support zone below the current price at 97.62, a Stop Loss order could be placed below this zone.

Looking into the high growth metrics of BLUEPRINT MEDICINES CORP

• With a favorable trend in its quarter-to-quarter (Q2Q) earnings per share (EPS), BLUEPRINT MEDICINES CORP highlights its ability to generate increasing profitability, showcasing a 59.55% growth.
• With impressive quarter-to-quarter (Q2Q) revenue growth of 127.0%, BLUEPRINT MEDICINES CORP showcases its ability to generate increased sales and revenue. This growth indicates the company's strong customer demand and its effective business strategies.
• The 1-year revenue growth of BLUEPRINT MEDICINES CORP (101.0%) has been strong, reflecting the company's ability to generate consistent sales growth. This growth suggests the company's ability to meet customer needs and expand its market share.
• The average next Quarter EPS Estimate for BLUEPRINT MEDICINES CORP has experienced a 36.17% change in the last 3 months, reflecting evolving expectations by analysts regarding the company's EPS performance.
• The quarterly earnings of BLUEPRINT MEDICINES CORP have shown a 59.55% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
• The earnings per share (EPS) growth of BLUEPRINT MEDICINES CORP are accelerating: the current Q2Q growth of 59.55% is above the previous year Q2Q growth of 1.35%. Earnings momentum and acceleration are key for high growth systems.
• With a favorable trend in its operating margin over the past year, BLUEPRINT MEDICINES CORP demonstrates its ability to enhance profitability through efficient operations. This growth reflects the company's focus on optimizing its cost structure.
• BLUEPRINT MEDICINES CORP has shown positive growth in its free cash flow (FCF) over the past year, indicating improved cash generation and financial strength. This growth highlights the company's ability to effectively manage its cash flows and generate surplus funds.
• Maintaining a Debt-to-Equity ratio of 1.09, BLUEPRINT MEDICINES CORP demonstrates a conservative financial approach. This signifies the company's focus on minimizing debt burdens while preserving a solid equity position.
• BLUEPRINT MEDICINES CORP has consistently exceeded EPS estimates in the last 4 quarters, demonstrating its ability to outperform market expectations. This trend highlights the company's strong financial performance and its potential for future growth.
• The Relative Strength (RS) of BLUEPRINT MEDICINES CORP has consistently been strong, with a current 75.2 rating. This indicates the stock's ability to exhibit relative price outperformance and reflects its competitive strength. BLUEPRINT MEDICINES CORP demonstrates promising potential for sustained price momentum.

More ideas for high growth momentum breakouts can be found on ChartMill in our High Growth Momentum Breakout screen.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.